A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-one analysts that are covering the firm, Marketbeat.com reports.

Eli Lilly recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside ...

President Donald Trump vowed to impose tariffs on pharmaceuticals within two weeks. Eli Lilly, a leader in the industry, could be harmed by the move, but it is already preparing for it.

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...

Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

That could be bad news for leaders in this sector, including Eli Lilly (NYSE: LLY), the largest pharmaceutical company in the world by market cap. Should investors give up on the stock?